Test Price
3,600 AEDโ Home Collection Available
Extended AML Panel (BCR/ABL, AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) โ Comprehensive Molecular Profiling
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Bone marrow aspiration โ Hospital Extraction Only. Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. If peripheral blood is approved by the ordering physician, VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection is available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed Consultant Medical Geneticist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genetic panel detects the seven most clinically actionable mutations in acute myeloid leukemia โ BCR/ABL, AML/ETO, CBFB, PML/RARA, FLT3, NPM1, and CEBPA โ using high-fidelity Sanger sequencing with bidirectional coverage. Designed for hematologists, medical oncologists, and hematopathologists, the test enables risk stratification, targeted therapy selection, and minimal residual disease monitoring with a 7โ8 working day turnaround. The panel reduces the need for multiple sequential tests by covering both fusion genes and nucleotide variants in a single assay.
| Feature | Our Extended AML Panel | Standard Regional Alternative |
|---|---|---|
| Precision/Method | Sanger Sequencing with bidirectional coverage, validated against CAP/ISO 15189 standards | FISH or qualitative PCR, limited gene coverage |
| Speed | 7โ8 calendar days | 10โ14 days |
| Sample Stability | Dedicated cold-chain home collection (peripheral blood) or immediate hospital processing (bone marrow) within 60 min, temperature logging | Ambient transport, risk of RNA degradation |
Physician Insight & Safety Protocols
โAs a DHA-licensed Consultant Medical Geneticist, I emphasize that the results of this panel must be interpreted within the full clinical context. A positive FLT3-ITD, for instance, demands urgent targeted therapy integration with appropriate tyrosine kinase inhibitors and should never delay induction chemotherapy. This test is a powerful tool but not a replacement for comprehensive bone marrow morphology and cytogenetics. Always correlate with peripheral blood blast count and patient performance status.โ โ Lina Osama Zaki Quteineh, DHA Registration ID: 9294403.
Advisory Notice
โ ๏ธ Do not discontinue prescribed medication without consulting your doctor. This includes anticoagulants, antiplatelet agents, and any AML induction therapy.
Exclusion Criteria & ER Red Flags
- Active severe infection or sepsis โ postpone elective bone marrow aspiration until stabilized.
- Uncorrected coagulopathy (INR > 1.5, platelets < 30ร10โน/L) โ risk of bleeding; requires hematology clearance before sampling.
- Pregnancy (unless in context of APL suspected PML/RARA) โ evaluate risk-benefit with fetal medicine specialist.
- Seek immediate ER care if you experience: sudden high fever (>38.5ยฐC), uncontrolled bleeding, severe bone pain, or neurological symptoms such as confusion, vision changes, or seizures after sampling.
Patient FAQ & Clinical Guidance
1. What is this AML panel ordered for and what does it detect?
This comprehensive genetic test identifies seven critical mutations that guide AML prognosis and targeted therapy selection, enabling personalized treatment decisions directly from a bone marrow or peripheral blood sample. It is ordered by hematologists and oncologists to risk-stratify newly diagnosed AML patients, detect minimal residual disease, and select tyrosine kinase inhibitors or all-trans retinoic acid when specific mutations are found. By covering both fusion genes and nucleotide variants, the panel reduces the need for multiple sequential tests and provides a complete mutational profile in one report.
2. How is the sample collected and do I need to fast or prepare?
Sample collection is performed either as a bone marrow aspiration (hospital-only procedure) or as a peripheral blood draw. For bone marrow aspiration, you will be scheduled at a DHA-licensed hospital. Peripheral blood can be collected at home via our VIP Mobile Phlebotomy service if approved by your physician. No fasting is required. Inform your doctor about all medications, especially blood thinners. A valid prescription is required for either collection method.
3. How long do results take and how are they interpreted?
Results are delivered within 7โ8 working days through a secure DHA-compliant portal and include a detailed molecular pathology report with clinically annotated variants. The report highlights each mutationโs clinical significance, associated risk category per ELN 2026 guidelines, and actionable drug targets. A post-test teleconsultation with a Consultant Medical Geneticist is included to explain implications and next steps.
UAE Regulatory & Data Privacy Adherence
Legal & Privacy Compliance: This service adheres strictly to Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data are processed within our DHA-licensed facility (License No. 1143) and stored on encrypted UAE-based servers. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) ensures continual quality improvement and traceability.
Clinical & Logistical Metadata
| Test Name | Extended AML Panel (BCR/ABL, AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) โ Molecular Profiling |
| Price (AED) | 3,600 |
| Turnaround Time | 7โ8 working days |
| Sample Type / Matrix | Bone marrow aspirate (hospital-only) or peripheral blood (home collection eligible) |
| Methodology Used | Sanger Sequencing with bidirectional coverage validated against CAP/ISO 15189 |
| ICD-10-CM Code | C92.00 (acute myeloblastic leukemia), C92.01 (in remission), D46.20 (MDS with single lineage dysplasia) |
| LOINC Code | 60560-5 (Acute myeloid leukemia gene rearrangement panel) |
| DHA Facility License & Laboratory Address Invariants | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians